Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments.

Braun RP, Dong L, Jerome S, Herber R, Roberts LK, Payne LG.

Hum Vaccin. 2008 Jan-Feb;4(1):36-43. Epub 2007 Aug 14.

PMID:
18438102
2.

Benefit of vitamin A supplementation on ascaris reinfection is less evident in stunted children.

Payne LG, Koski KG, Ortega-Barria E, Scott ME.

J Nutr. 2007 Jun;137(6):1455-9.

PMID:
17513406
3.

Hepatitis-B surface antigen (HBsAg) powder formulation: process and stability assessment.

Maa YF, Ameri M, Shu C, Zuleger CL, Che J, Osorio JE, Payne LG, Chen D.

Curr Drug Deliv. 2007 Jan;4(1):57-67.

PMID:
17269918
5.

Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin.

Haynes JR, Arrington J, Dong L, Braun RP, Payne LG.

Vaccine. 2006 Jun 5;24(23):5016-26. Epub 2006 Mar 31.

PMID:
16621198
6.

Peptide induces CD4(+)CD25+ and IL-10+ T cells and protection in airway allergy models.

Zuleger CL, Gao X, Burger MS, Chu Q, Payne LG, Chen D.

Vaccine. 2005 May 2;23(24):3181-6.

PMID:
15837218
7.

An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model.

Burger MS, Zuleger CL, Chu Q, Gao X, Payne LG, Chen D.

J Allergy Clin Immunol. 2004 Dec;114(6):1301-8.

PMID:
15577827
8.

Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.

Maa YF, Ameri M, Shu C, Payne LG, Chen D.

J Pharm Sci. 2004 Jul;93(7):1912-23.

PMID:
15176078
9.

Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity.

Chen D, Burger M, Chu Q, Endres R, Zuleger C, Dean H, Payne LG.

Virus Res. 2004 Jul;103(1-2):147-53.

PMID:
15163503
10.

Grading follicular lymphoma on fine needle aspiration specimens. Comparison with proliferative index by DNA image analysis and Ki-67 labeling index.

Sun W, Caraway NP, Zhang HZ, Khanna A, Payne LG, Katz RL.

Acta Cytol. 2004 Mar-Apr;48(2):119-26.

PMID:
15085740
11.

Spray-coating for biopharmaceutical powder formulations: beyond the conventional scale and its application.

Maa YF, Ameri M, Rigney R, Payne LG, Chen D.

Pharm Res. 2004 Mar;21(3):515-23.

PMID:
15070104
12.

Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization.

Maa YF, Shu C, Ameri M, Zuleger C, Che J, Osorio JE, Payne LG, Chen D.

Pharm Res. 2003 Jul;20(7):969-77.

PMID:
12880281
13.

Epidermal powder immunization of mice and monkeys with an influenza vaccine.

Chen D, Endres R, Maa YF, Kensil CR, Whitaker-Dowling P, Trichel A, Youngner JS, Payne LG.

Vaccine. 2003 Jun 20;21(21-22):2830-6.

PMID:
12798624
14.

Immune responses to hepatitis B surface antigen following epidermal powder immunization.

Osorio JE, Zuleger CL, Burger M, Chu Q, Payne LG, Chen D.

Immunol Cell Biol. 2003 Feb;81(1):52-8.

PMID:
12534946
15.

Stabilization of alum-adjuvanted vaccine dry powder formulations: mechanism and application.

Maa YF, Zhao L, Payne LG, Chen D.

J Pharm Sci. 2003 Feb;92(2):319-32.

PMID:
12532382
16.

Particle-mediated DNA vaccination of mice, monkeys and men: looking beyond the dogma.

Payne LG, Fuller DH, Haynes JR.

Curr Opin Mol Ther. 2002 Oct;4(5):459-66. Review.

PMID:
12435047
17.

Epidermal powder immunization with a recombinant HIV gp120 targets Langerhans cells and induces enhanced immune responses.

Chen D, Zuleger C, Chu Q, Maa YF, Osorio J, Payne LG.

AIDS Res Hum Retroviruses. 2002 Jul 1;18(10):715-22.

PMID:
12167279
18.

Targeting epidermal Langerhans cells by epidermal powder immunization.

Chen D, Payne LG.

Cell Res. 2002 Jun;12(2):97-104. Review.

19.

Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity.

Chen D, Endres RL, Erickson CA, Maa YF, Payne LG.

Vaccine. 2002 Jun 21;20(21-22):2671-9.

PMID:
12034092
20.

Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

Arrington J, Braun RP, Dong L, Fuller DH, Macklin MD, Umlauf SW, Wagner SJ, Wu MS, Payne LG, Haynes JR.

J Virol. 2002 May;76(9):4536-46.

21.

Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.

Chen D, Weis KF, Chu Q, Erickson C, Endres R, Lively CR, Osorio J, Payne LG.

J Virol. 2001 Dec;75(23):11630-40.

22.

Serum and mucosal immune responses to an inactivated influenza virus vaccine induced by epidermal powder immunization.

Chen D, Periwal SB, Larrivee K, Zuleger C, Erickson CA, Endres RL, Payne LG.

J Virol. 2001 Sep;75(17):7956-65.

23.

Adjuvantation of epidermal powder immunization.

Chen D, Erickson CA, Endres RL, Periwal SB, Chu Q, Shu C, Maa YF, Payne LG.

Vaccine. 2001 Apr 6;19(20-22):2908-17.

PMID:
11282202
24.

Epidermal immunization by a needle-free powder delivery technology: immunogenicity of influenza vaccine and protection in mice.

Chen D, Endres RL, Erickson CA, Weis KF, McGregor MW, Kawaoka Y, Payne LG.

Nat Med. 2000 Oct;6(10):1187-90. No abstract available.

PMID:
11017153
25.

Polymeric carriers for oral uptake of microparticulates.

Andrianov AK, Payne LG.

Adv Drug Deliv Rev. 1998 Dec 1;34(2-3):155-170.

PMID:
10837676
26.

Protein release from polyphosphazene matrices.

Payne LG, Andrianov AK.

Adv Drug Deliv Rev. 1998 May 4;31(3):185-196.

PMID:
10837625
27.

Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions.

Andrianov AK, Chen J, Payne LG.

Biomaterials. 1998 Jan-Feb;19(1-3):109-15.

PMID:
9678857
28.

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine.

Payne LG, Jenkins SA, Woods AL, Grund EM, Geribo WE, Loebelenz JR, Andrianov AK, Roberts BE.

Vaccine. 1998 Jan;16(1):92-8.

PMID:
9607015
29.

PCPP as a parenteral adjuvant for diverse antigens.

Payne LG, Van Nest G, Barchfeld GL, Siber GR, Gupta RK, Jenkins SA.

Dev Biol Stand. 1998;92:79-87.

PMID:
9554261
30.

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

Lu Y, Salvato MS, Pauza CD, Li J, Sodroski J, Manson K, Wyand M, Letvin N, Jenkins S, Touzjian N, Chutkowski C, Kushner N, LeFaile M, Payne LG, Roberts B.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):99-106.

PMID:
8680896
31.

Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene.

Roper RL, Payne LG, Moss B.

J Virol. 1996 Jun;70(6):3753-62.

32.

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery.

Payne LG, Jenkins SA, Andrianov A, Roberts BE.

Pharm Biotechnol. 1995;6:473-93. Review.

PMID:
7551232
33.

Xenobiotic polymers as vaccine vehicles.

Payne LG, Jenkins SA, Andrianov A, Langer R, Roberts BE.

Adv Exp Med Biol. 1995;371B:1475-80. No abstract available.

PMID:
7502840
34.

Host range selection of vaccinia recombinants containing insertions of foreign genes into non-coding sequences.

Smith KA, Stallard V, Roos JM, Hart C, Cormier N, Cohen LK, Roberts BE, Payne LG.

Vaccine. 1993;11(1):43-53.

PMID:
8427036
35.

Recombinant-expressed virus-like particle pseudotypes as an approach to vaccine development.

McGuigan LC, Stallard V, Roos JM, Payne LG.

Vaccine. 1993;11(6):675-8.

PMID:
8322492
37.

Molecular attenuation of vaccinia virus: mutant generation and animal characterization.

Lee MS, Roos JM, McGuigan LC, Smith KA, Cormier N, Cohen LK, Roberts BE, Payne LG.

J Virol. 1992 May;66(5):2617-30.

38.
39.

Vaccinia recombinants as vaccine vectors.

Mahr A, Payne LG.

Immunobiology. 1992 Feb;184(2-3):126-46. Review. No abstract available.

PMID:
1587539
41.

The polypeptide composition of vaccinia-infected cell membranes and rifampicin bodies.

Payne LG, Kristensson K.

Virus Res. 1990 Aug;17(1):15-30.

PMID:
2220070
42.

Protein footprinting method for studying antigen-antibody interactions and epitope mapping.

Sheshberadaran H, Payne LG.

Methods Enzymol. 1989;178:746-64. No abstract available.

PMID:
2481222
45.

Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo.

Payne LG, Kristensson K.

J Gen Virol. 1985 Mar;66 ( Pt 3):643-6.

PMID:
3973566
46.

Synthesis of N2-[(S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline (lisinopril).

Wu MT, Douglas AW, Ondeyka DL, Payne LG, Ikeler TJ, Joshua H, Patchett AA.

J Pharm Sci. 1985 Mar;74(3):352-4.

PMID:
2989485
47.
48.

The effect of cytochalasin D and monensin on enveloped vaccinia virus release.

Payne LG, Kristensson K.

Arch Virol. 1982;74(1):11-20.

PMID:
6891579
49.

Inhibition of thermolysin by N-carboxymethyl dipeptides.

Maycock AL, DeSousa DM, Payne LG, ten Broeke J, Wu MT, Patchett AA.

Biochem Biophys Res Commun. 1981 Oct 15;102(3):963-9. No abstract available.

PMID:
7306200
50.

A new class of angiotensin-converting enzyme inhibitors.

Patchett AA, Harris E, Tristram EW, Wyvratt MJ, Wu MT, Taub D, Peterson ER, Ikeler TJ, ten Broeke J, Payne LG, Ondeyka DL, Thorsett ED, Greenlee WJ, Lohr NS, Hoffsommer RD, Joshua H, Ruyle WV, Rothrock JW, Aster SD, Maycock AL, Robinson FM, Hirschmann R, Sweet CS, Ulm EH, Gross DM, Vassil TC, Stone CA.

Nature. 1980 Nov 20;288(5788):280-3.

PMID:
6253826

Supplemental Content

Loading ...
Support Center